Prime Medicine
PRME
192 hedge funds and large institutions have $343M invested in Prime Medicine in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 74 increasing their positions, 49 reducing their positions, and 25 closing their positions.
56% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 25
51% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 49
27% more call options, than puts
Call options by funds: $3.62M | Put options by funds: $2.86M
5% more funds holding
Funds holding: 183 → 192 (+9)
2% more capital invested
Capital invested by funds: $336M → $343M (+$6.07M)
0.86% more ownership
Funds ownership: 53.73% → 54.59% (+0.86%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$7.51M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$6.05M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.76M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.8M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.99M |
| 2 |
Morgan Stanley
New York
|
-$2.02M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$1.95M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.91M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.75M |
PRME Hedge Fund Activity: Q1 2026 in Review
192 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q1 2026, worth a combined $343M — up 1.8% from $336M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new PRME positions and 25 closed out — a net gain of 14 holders — while 74 added to existing stakes and 49 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $7.51M. The largest seller was Goldman Sachs, cutting an estimated $2.99M.
- 192 institutional investors held Prime Medicine (PRME) as of Q1 2026, up from 183 in Q4 2025.
- Funds reported $343M of Prime Medicine stock for Q1 2026, up 1.8% quarter-over-quarter.
- 39 funds opened new Prime Medicine positions in Q1 2026 and 25 closed out, a net change of +14 holders.
- The largest Prime Medicine buyer in Q1 2026 was ADAR1 Capital Management, an estimated $7.51M added.
- The largest Prime Medicine seller in Q1 2026 was Goldman Sachs, an estimated $2.99M sold.
Based on aggregated 13F filings for Q1 2026.